/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Legend Biotech Corp Share Price Today: Live Updates & Key Insights

Legend Biotech Corp share price today is $19.15, up -6.02%. The stock opened at $20.2 against the previous close of $20.27, with an intraday high of $20.2 and low of $19.055.

Legend Biotech Corp Share Price Chart

style
pb-0

Legend Biotech Corp

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Legend Biotech Corp Share Price Performance

$19.15 -0.0602(-6.02%) LEGN at 13 Mar 2026 01:56 PM Biotechnology
Lowest Today 19.055
Highest Today 20.2
Today’s Open 20.2
Prev. Close 20.27
52 Week High 45.30
52 Week Low 16.24
Day’s Range: Low 19.055 High 20.2
52-Week Range: Low 16.24 High 45.30
1 day return -
1 Week return +0.34
1 month return +8.26
3 month return -13.38
6 month return -43.75
1 year return -49.93
3 year return -57.96
5 year return -26.57
10 year return -

Legend Biotech Corp Institutional Holdings

FMR Inc 13.14

Suvretta Capital Management, LLC 3.58

Westfield Capital Management Company, L.P. 3.34

Hillhouse Capital Advisors, Ltd. 3.24

Deerfield Management Co 3.21

Fidelity OTC 2.54

BlackRock Inc 2.43

Fidelity Select Health Care 2.14

Artisan Partners Limited Partnership 1.27

Fidelity VIP Contrafund Initial 1.16

HHG PLC 1.15

Jupiter Merian Glb Eq AbsRet I USD Acc 1.13

Fidelity Advisor Health Care I 1.11

Strategic Advisers Fidelity US TtlStk 1.00

AllianceBernstein L.P. 0.88

Fidelity Select Pharmaceuticals Port 0.88

Artisan International Small-Mid Investor 0.78

Artisan Non-U.S. Small-Mid Growth Comp 0.78

BRAIDWELL LP 0.70

Fidelity Advisor New Insights I 0.70

State Street Corp 0.63

Federated Hermes Inc 0.58

Davern Capital Partners, L.P. 0.57

The Goldman Sachs Group Inc 0.57

iShares Biotechnology ETF 0.56

Matthews International Cap Mgmt LLc 0.56

UBS Group AG 0.55

Capital Research & Mgmt Co - Division 3 0.51

American Funds SMALLCAP World A 0.49

TANG CAPITAL MANAGEMENT LLC 0.45

iShares Core MSCI Emerging Markets ETF 0.45

Johnson & Johnson 0.44

IvyRock Asset Management (HK) Ltd 0.44

Fidelity OTC Commingled Pool Class D 0.43

Harbor Small Cap Growth Instl 0.40

Westfield Capital Mgt Co Sm-Cap Gr Eq 0.40

Fidelity VIP Health Care Initial 0.37

HBM Healthcare Investments AG Ord 0.32

Fidelity Series Opportunistic Insights 0.32

Westfield Small/Mid Cap Grow Eq CIT CL C 0.29

Legend Biotech Corp Market Status

Strong Buy: 11

Buy: 10

Hold: 1

Sell: 0

Strong Sell: 0

Legend Biotech Corp Fundamentals

Market Cap 3743.66 M

PB Ratio 3.702

PE Ratio 0.0

Enterprise Value 3161.30 M

Total Assets 1733.71 M

Volume 1332542

Legend Biotech Corp Company Financials

Annual Revenue FY23:233312000 233.3M, FY22:117005000 117.0M, FY21:89792000 89.8M, FY20:75676000 75.7M, FY19:57264000 57.3M

Annual Profit FY23:98584000 98.6M, FY22:51642000 51.6M, FY21:89792000 89.8M, FY20:75676000 75.7M, FY19:57264000 57.3M

Annual Net worth FY23:-509312000 -509.3M, FY22:-446349000 -446.3M, FY21:-386209000 -386.2M, FY20:-303477000 -303.5M, FY19:-132972000 -133.0M

Quarterly Revenue Q3/2025:272330000 272.3M, Q2/2025:255058000 255.1M, Q1/2025:195053000 195.1M, Q3/2024:160205000 160.2M, Q2/2024:186523000 186.5M

Quarterly Profit Q3/2025:157024000 157.0M, Q2/2025:157067000 157.1M, Q1/2025:123709000 123.7M, Q3/2024:104736000 104.7M, Q2/2024:136072000 136.1M

Quarterly Net worth Q3/2025:-39689000 -39.7M, Q2/2025:-125380000 -125.4M, Q1/2025:-100916000 -100.9M, Q3/2024:-125321000 -125.3M, Q2/2024:-18196000 -18.2M

About Legend Biotech Corp & investment objective

Company Information Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.

Organisation Biotechnology

Employees 3000

Industry Biotechnology

CEO null

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow